Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha® (evolocumab injection) for eligible patients following an acute coronary syndrome ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results